Fulcrum Therapeutics Secures Exclusive Global License Agreement in Rare Hematology   In a significant development, Fulcrum Therapeutics, Inc. has recently announced the signing of an exclusive worldwide license agreement with CAMP4 Therapeutics Corp. The objective of this partnership is to advance the discovery, development, and commercialization of innovative therapeutic solutions for Diamo..
Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company specializing in therapies for chronic inflammatory diseases, unveiled additional findings from its pivotal trial for atopic dermatitis during the 2023 World Congress of Dermatology. The data highlighted the effectiveness and safety of rademikibart (formerly known as CBP-201) in treating moderate-to-severe atopi..
Clearside Biomedical's Asia-Pacific partner, Arctic Vision, has announced that its new drug application for the suprachoroidal use of Arcatus® in treating Uveitic Macular Edema has been accepted in Australia. This exciting development comes as Clearside Biomedical, Inc., a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®..
MIT Professor Cleared of Misconduct After Years of Scrutiny After a thorough investigation lasting 3.5 years, Ram Sasisekharan, a professor at the Massachusetts Institute of Technology (MIT), has been cleared of misconduct allegations in March 2023. While Dartmouth College professor Tillman Gerngross and his colleagues maintain their accusations against Sasisekharan, other accusers did not respo..
TellBio, Inc., a biotechnology company specializing in cancer detection, has recently published two manuscripts that highlight the potential applications of its TellDx platform in prostate cancer and advanced breast cancer. The papers, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cul..
Less than half of the new drug approvals are actually providing therapeutic value to patients, according to a recent study published in The BMJ. Despite the increasing number of drugs being approved in both the U.S. and Europe, it seems that many of them are not significantly improving patient outcomes. The study focused on 124 first indications that were approved by the FDA and European Medicin..
UMCG in the Netherlands has recently acquired Micro-RayStation, a research software platform developed by RaySearch Laboratories. This software is specifically designed for pre-clinical research involving radiation treatment planning and plan evaluation in small animals. RaySearch Laboratories AB (publ) has announced that University Medical Center Groningen (UMCG) in the Netherlands has placed a..
Abeona Therapeutics Inc. (Nasdaq: ABEO) has successfully completed a registered direct offering, raising an impressive $25 million in gross proceeds. What's even more remarkable is that this offering was carried out without any discounts or warrant coverage, highlighting the unwavering confidence of existing institutional investors in Abeona. The purpose behind this fundraising success is to pre..
